177 related articles for article (PubMed ID: 38670723)
1. Patient Voices in Rheumatic Immune-related Adverse Events.
Corps KN; Terry O; Lopez-Olivo MA
Rheum Dis Clin North Am; 2024 May; 50(2):241-254. PubMed ID: 38670723
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
Thanarajasingam U; Abdel-Wahab N
Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
[TBL] [Abstract][Full Text] [Related]
5. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
6. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
7. Imaging in Rheumatic Immune-related Adverse Events.
Zhang J; Ni R; Oke I; Calabrese C; Strouse J; Weinmann S; Ladouceur A
Rheum Dis Clin North Am; 2024 May; 50(2):313-323. PubMed ID: 38670729
[TBL] [Abstract][Full Text] [Related]
8. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
[TBL] [Abstract][Full Text] [Related]
9. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
10. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
[TBL] [Abstract][Full Text] [Related]
11. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
[TBL] [Abstract][Full Text] [Related]
12. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
13. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
14. Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
16. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
17. [Rheumatological complications of immune checkpoint inhibitor therapy].
Lazarou I; Fernandez E
Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
[TBL] [Abstract][Full Text] [Related]
18. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
Chan KK; Bass AR
Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
[TBL] [Abstract][Full Text] [Related]
19. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
[TBL] [Abstract][Full Text] [Related]
20. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]